Wells Fargo Downgrades Ironwood Pharmaceuticals (IRWD) to Equal Weight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
Go back to Wells Fargo Downgrades Ironwood Pharmaceuticals (IRWD) to Equal Weight
April 15, 2025 2:54 AM EDT
Jefferies analyst Amy Li downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Buy to Hold with a price target of $0.70 (from $8.00).
The analyst comments: "Stepping back, we believed that glepa's CRL wouldn't read across to IRWD given apra's more robust clinical package at the to-be-marketed dose &... More
April 14, 2025 11:35 AM EDT
Citizens JMP analyst Jason Butler downgraded Ironwood Pharmaceuticals (NASDAQ: IRWD) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.
Shares of Ironwood Pharmaceuticals closed at $0.95 yesterday.
...
More
April 14, 2025 10:29 AM EDT
Leerink Partners analyst Faisal A. Khurshid lowered the price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) to $1.00 (from $3.00) while maintaining a Market Perform rating.
The analyst comments "IRWD announced they will need to run an additional confirmatory Ph 3 trial for apraglutide in short... More
April 14, 2025 7:02 AM EDT
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that, based on a recent discussion with the U.S. Food and Drug Administration (FDA), a confirmatory Phase 3 trial is needed to seek approval of apraglutide... More
